Extensive patent portfolios, frequently described as thickets, cover biologic drug products and serve as significant barriers to entry for companies seeking to market follow-on products. Those companies must make a number of strategic choices as they work within a complicated statutory scheme to position themselves for patent litigation that will determine when they can launch their products. This program will examine the lessons learned from litigations brought pursuant to the Biologics Price Competition and Innovation Act and the strategies that companies are pursuing to streamline litigation, navigate the patent thicket, and get to market faster.